This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any



Cardiovascular

$ 66.8mn **-29.9%YOY**

Surgical Robot

IPO application accepted

Note: Revenue growth rate adjusted to exclude foreign exchange impact
* Including CRM $150mn equity fund raising announced in Jul 21

Successful External Financing & Strategic Investment



Raised

Note: Electrophysiology business under associated company

Product Highlights & Clinical Progress

Domestic

NMPA Approvals* — **1** product entered Green Path; **21** products accumulatively - **No.1** in industry

Cardio-vascular	✦ Firesorb® **FUTURE-II trial** 1-year results proved comparable angiographic and clinical efficacy to -eluting stents
Ortho-pedics	✦ Profemur® Femoral Stem & VenusOne Bio-acetabular system in **registration stage**
CRM	✦ Platinium ICDs, Platinium CRT-Ds & BeFlex MRI lead **submitted for approval** ✦ ENO /TEO /OTO pacemakers & Vega lead finished **CAPRI 1st** clinical enrollment
Endo-vascular	✦ Talos® Thoracic Stent Graft & Fontus® Surgical Stent Graft **submitted for approval** ✦ TIPS Stent Graft completed animal study
Neuro-vascular	✦ **NUMEN® Silk** 3-D Coil Embolization System, Intracranial Distal Access Catheter & **Diveer** Intracranial Balloon Catheter **submitted for approval** ✦ Tubridge® completed patient enrollment of IMPACT trail (Aug 21)
Surgical Robot	✦ **DFVision®** 3D Electronic Laparoscope (Ultra HD) **submitted for approval** ✦ **Toumai®** Laparoscopic Surgical Robot **submitted for approval** ✦ **Honghu** Orthopedic Surgical Robot **submitted for approval** (Jul 21)

Overseas

CE Approvals — **FDA Approvals**

Note: 1. Electrophysiology & Assisted Reproductive Technology (ART) businesses under associated companies; 2. Unless otherwise stated, all R&D progresses occurred in 1H2021
*including Alwide® Plus (approved by NMPA in Aug 21)

Professional Platforms Providing One-stop Medical Solutions

Nonvascular Intervention

Provide solutions to **urinary, gynecological, digestive & respiratory** diseases

2 products newly **approved by NMPA**; **2** in registration stage

Ureteroscope upon launch with multiple single-use scope product lines

Kidney stone management product covered **70+** hospitals

Sports Medicine

Complete sports medicine portfolio with innovative & robust shoulder solutions

The 1st long-term implantable rotator cuff spacer system, with proved clinical evidence

4 products upon NMPA approval

Assisted Reproductive Technology

Orkid® Intrauterine Insemination Catheter newly **approved by NMPA**

Embryo Transfer Catheter & Ovum Aspiration Needle newly **approved** in Thailand

Rehabilitation

Focus on **muscle & bone** rehabilitation, **cardiopulmonary** rehabilitation and **neurological** rehabilitation

6 approved products with multiple product lines

Obtained **~100** patents

Endocrinology

Core platform: micro-infusion technology

La Fenice® Insulin Pump sales increased substantially, owing to online channels development

Chemotherapy pump in registration stage

IVD

High-tech diagnostic solution provider

Self-developed 2019-nCoV PCR Test Kit **approved by CE**

Medical Imaging

Provide precise interventional imaging solution

DSA in **NMPA** registration stage

Aesthetic

Provide solutions incl. **facial rejuvenation, body contouring** & **hair Loss treatment**

ENT, Ophthalmology & Dental

Ophthalmological treatment: cataract, ametropia & glaucoma

Innovative solutions: sinus, inner ear drug delivery system & artificial hearing repair

Orthodontics & dental implant

Sterilization

Obtained certificates: ISO13485 & ISO11135, Japan Registration Certificate

Rapid revenue growth driven by **increased customer base**

Contents

1 Interim Result Highlights

2 Financial Review

3 Business Review

4 Outlook

5 Appendix Financial Statements

Operating Expenses

Sales & Marketing Expenses

USD: million



Sales & marketing expenses increased by 16.7% YOY

- Increase in marketing activities as Covid-19 pandemic came under control

Administrative Expenses

USD: million



Administrative expenses increased by 13.7% YOY

- Increase in staff cost

R&D Expenses

USD: million



R&D expenses increased by 60.8% YOY

- Due to increased investments in R&D projects

Cash Flow

Net Cash Flow from Operating Activities

USD: million

Net Cash Flow used in Investing Activities

USD: million



Net Cash Flow from Financing Activities

USD: million

Net operating cash flow decreased by $114.8mn

Contents

1 Interim Result Highlights

2 Financial Review

3 Business Review

4 Outlook

5 Appendix Financial Statements

Cardiovascular Business

Business Highlights



Product Pipeline



Business by Sector

DES

Balloon

- **Domestic: 1H 2021 revenue $8.6mn, 88.5% YOY**
  - Penetrated **280+** hospitals with hospital coverage reaching **1,000+**
  - Sales volume increased by **114% YOY**
- **Overseas: 1H 2021 revenue $0.9mn, 26.0% YOY**
  - **7** new registration approvals in **4** countries/regions, further expanding global footprint

MicroPort微创

Note: Revenue growth rate adjusted to exclude foreign exchange impact

Orthopedics Business (Non-China Business

Non-China Business Highlights

Revenue

USD: million

Revenue Breakdown by Region

5 CE & 2 FDA approvals

CE:3087]TJETQ EMC /P <MCBT/F1 935q0.00 EMC /P <MCID 91/Lang (en-GBT/F4 9.96 Tf1 0 07 115.75 175.99 Tm0 g 3(tration)]TJETQ4.47 Tm461.4 504.52 461.4 c635q0.00 EMC /P <0.000014305

Extensive Product Pipeline

Product	Pre-clinical	Clinical	Registration
Prime® Constrained Liner and Multi-hole Acetabular Cup System			Submitted for FDA application
DYNASTY® Dual Mobility Acetabular Hip System			Submitted for FDA application
Additive Manufactured Prime® Acetabular Cup			Submitted for FDA application
Evolution® Kinematic Alignment instrumentation			Obtained FDA & CE certification
Anterior PATH® instrumentation			Obtained FDA & CE certification
Proximal Cemented XM® Femoral Stem			Obtained CE certification
Procotyl® P Revision Acetabular Cup System			Obtained CE certification
Hip Head Tensioner Device			Obtained CE certification

Orthopedics Business (China Business)

China Business Highlights

USD: million

Revenue



Revenue Breakdown by Product Type



Evolution® Medial-Pivot Knee System and **FemurElite-S Hip System** entered **Group A** of GPO, expected to further increase market share

Business by Sector

Joints

- **1H 2021 revenue: $12.3mn, +32.0% YOY**
- Sales substantially increased; penetrated **400+** hospitals with total coverage of **~950** hospitals
- Made-in-China hip products, launched in 2020, realized substantial sales growth of **593.4% YOY**, covering **256** hospitals
- **Advance®** Medial-Pivot Knee System received **15 ODEP** (Orthopedic Data Evaluation Panel) **1st Chinese company** to receive the **highest** ODEP rating
- **Cost reduced** for joint instrument by roughly **30% YOY** while **production capacity nearly tripled**

Spine & Trauma

- **1H 2021 revenue: $2.5mn, +83.7% YOY**
- Robust sales growth contributed by **sales channels expansion** and **new product launches** in 2020 (**Piscis® II** Injectable Artificial Bone Fusion Cage & **Takin® II** Hollow Spine Minimally Invasive System)

Comprehensive Made-in-China Product Pipeline

Note: Revenue growth rate adjusted to exclude foreign exchange impact

Non-China Business Highlights

Non-China Revenue

USD: million

Sales Highlights

- **1H 2021 revenue: $102.3mn, +17.3% YOY**
- Global sales gradually recovered with profitability improved
- Realized robust sales growth of **+87.3%** in US, **45.8%** in Japan and **+16.1%** in EMEA
- Launched **Alizea** /**Borea** pacemakers in Europe with large-scale commercial deployment

6 CE approvals

Alizea /**Borea** Bluetooth® pacemakers
SmartView home monitor
Ulys /**Edis** /**Gali** ICD & CRT-D

- **Invicta** ICD lead launched clinical trial

China Business Highlights

China Revenue

USD: million

Sales Highlights

- **1H 2021 revenue:**

- Submission of registration to **NMPA**: **Platinium** ICDs, **Platinium** CRT-Ds, and **BeFlex** MRI lead
- **ENO** /**TEO** /**OTO** pacemakers and **Vega** lead completed 1st patient enrollment in **CAPRI** study
- **BonaFire** passive pacing lead is under clinical trail

Product Pipeline for Non-China Business



Product Pipeline for China Business



Neurovascular Business

Business Highlights



Sales Highlights

- **1H 2021 revenue: $25.4mn, +114.5% YOY**
- revenue +89.5% YOY, newly penetrating **105** hospitals with total coverage of **1,372** hospitals, remaining as **No.1 player** in Intracranial stenosis treatment
- Tubridge® revenue more than doubled with hospital coverage totaling **475** hospitals
- Strong sales growth drives from **new product launches**: NUMEN® Coil Embolization System, NUMEN FR® Coil Detachment System and U-track® Intracranial Support Catheter System

- NUMEN® & NUMEN FR® **approved** by **CE**
- NUMEN® completed **1st overseas commercial implantation** in Chile in Aug 2021

- Led **$50mn** equity investment in **Rapid Medical** **Top 1 shareholder**
- As **exclusive distributor**

Extensive Product Pipeline

Neurohawk Thrombectomy Device		Submitted for NMPA review
Tigertriever Revascularization Device		In preparation for registration approval
Intracranial Distal Access Catheter		Submitted for NMPA review
Diveer Balloon Catheter		Submitted for NMPA review
Balloon Protection Guiding Catheter		Design stage
NUMEN® Silk 3-D Coil Embolization System		Submitted for NMPA review
Tubridge® II Vascular Reconstruction Device		Design stage

Heart Valve Business

Business Overview



IPO

- **Successful spin-off and separate listing on HKEx** (4 Feb 2021)
- **Net IPO proceeds:** HKD **2,717.2mn** (~$360mn)

MicroPort 心通医疗 2160.HK

Business Highlights

1H 2021 revenue $13.4mn, +121.8% YOY

GP margin expanded 110bps to 55.1% due to better cost control & scale economies

- **Extensive nationwide coverage** with fast-growing market share
  - Penetrated **76** hospitals in 1H 2021, with total coverage of **220** hospitals
  - Covered **19** out of **Top 20** hospitals
  - **No.1** market position in approx. 100 hospitals
- Subsidiary **Chengdu Xintuo** opened in May 2021, expected to secure key raw materials and further improve profitability
- VitaFlow completed **1st overseas commercial implantation** in Argentina in Aug 2021
- VitaFlow® -year follow-up study showed the rates of all-cause mortality and major stroke were **12.7%** and **2.7%**, respectively, further **proving the safety and efficacy** for long-term clinical use

Extensive Product Pipeline with Solid Progress

	Pre-clinical	
VitaFlow Liberty		**Expected to be approved by NMPA**
VitaFlow® III		Design fixing
VitaFlow® Balloon Expandable		Design stage
In-house Developed Replacement Product		Under animal studies
AltaValve		Under early feasibility study
		Under animal studies
In-house Developed Edge to Edge		Design fixing
		Under clinical trial
Trivid Repair Product		Design stage
Edge to Edge Repair Product		Design stage
Surgical Valve		Design stage
Alwide® Plus Balloon Catheter		**Obtained NMPA approval in Aug 2021**

Surgical Robot Business

Business Overview

Extensive Product Pipeline

	Pre-clinical	Clinical	Registration
Toumai® Laparoscopic Surgical Robot			Submitted for NMPA approval
DFVision® 3D Electronic Laparoscope			**Obtained NMPA approval**
Honghu Orthopedic Surgical Robot			Submitted for NMPA approval[1]
Spine Surgical Robot		Design stage	
Trans-bronchial Surgical Robot		Design stage	
TAVR Surgical Robot		Design stage	
R-One Vascular Interventional Surgical Robot		Design verification stage in China Obtained CE mark in 2019	
Automated Needle Targeting Robotics System		Design stage in China Obtained CE mark[2] in 2020	
Mona Lisa Robotic Transperineal Prostate Biopsy System Mona Lisa		Design verification stage in China Obtained CE & FDA approval in 2017	

Note: 1. Submitted in July 2021; 2. For the indication in percutaneous nephrolithotomy

Contents

1 Interim Result Highlights

2 Financial Review

3 Business Review

4 Outlook

5 Appendix Financial Statements

Innovative Product Pipeline Fueling Long-Term Growth

Cardio-vascular	Firehawk®

Contents

1 Interim Result Highlights

2 Financial Review

3 Business Review

4 Outlook

5 Appendix Financial Statements

Appendix I - Consolidated Income Statement

USD'000	1H 2021	1H 2020	Var.
Revenue	384,611	306,922	25.3%
Cost of sales	(137,003)	(89,334)	53.4%
Gross profit	**247,608**	**217,588**	**13.8%**
Other net income	24,622	30,808	-20.1%
Research and development costs	(117,064)	(72,803)	60.8%
Distribution cost	(130,689)	(111,972)	16.7%
Administrative expenses	(102,987)	(90,614)	13.7%
Other operating costs	(5,466)	(9,611)	-43.1%
Loss from operations	**(83,976)**	**(36,604)**	**129.4%**
Finance cost	(21,905)	(16,071)	36.3%
Gain on deemed disposal of a subsidiary	8,219	-	N/A
Gain on deemed disposal of interest in equity-accounted investees	523	-	N/A
Share of losses of equity-accounted investees	(5,255)	(2,522)	108.4%
Loss before taxation	**(102,394)**	**(55,197)**	**85.5%**
Income tax	(12,282)	(13,565)	-9.5%
Loss for the period	**(114,676)**	**(68,762)**	**66.8%**
Attributable to: Equity shareholders of the Company	**(90,266)**	**(65,562)**	**37.7%**

Appendix II - Consolidated Balance Sheet

USD'000	30 June 2021	31 Dec 2020	Var.
Non-current assets			
Investment properties	16,669	5,284	215%
Other property, plant and equipment	483,620	481,203	1%
Intangible assets	143,403	138,397	4%
Prepayments for non-current assets	10,184	7,724	32%
Goodwill	157,423	159,483	-1%
Equity-accounted investees	321,656	87,063	269%
Other financial assets	26,627	19,605	36%
Deferred tax assets	14,109	15,502	-9%
Other non-current assets	101,630	75,009	35%
Total non-current assets	**1,275,321**	**989,270**	**29%**
Current assets			
Inventories	244,203	240,187	2%
Trade and other receivables	249,273	236,976	5%
Pledged deposits and time deposits	13,622	623	2087%
Cash and cash equivalents	1,699,410	1,002,077	70%
Derivative financial assets	1,480	-	N/A
Total current assets	**2,207,988**	**1,479,863**	**49%**
Current liabilities			
Trade and other payables	239,409	372,472	-36%
Contract liabilities	39,297	62,008	-37%
Lease liabilities	15,492	12,074	28%
Interest-bearing borrowings	58,436	10,891	437%
Income tax payable	4,091	52,682	-92%
Derivative financial liabilities	-	9,252	-100%
Total current liabilities	**356,725**	**519,379**	**-31%**
Net current assets	**1,851,263**	**960,484**	**93%**

Appendix II - Consolidated Balance Sheet

USD'000	30 June 2021	31 Dec 2020	Var.
Non-current liablities			
Interest-bearing borrowings	119,323	181,988	-34%
Lease liabilities	50,921	42,774	19%
Deferred income	33,383	37,844	-12%
Convertible bonds	720,492	48,583	1383%
Contract liabilities	29,486	29,855	-1%
Other payables	109,348	203,023	-46%
Deferred tax liabilities	4,111	4,122	0%
Derivative financial liabilities	7,124	13,619	-48%
Total non-current liablities	**1,074,188**	**561,808**	**91%**
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	1,472,443	1,127,945	31%
Total equity attributable to equity shareholders of the Company	**1,472,461**	**1,127,963**	**31%**
Non-controlling interests	579,935	259,983	123%
Total equity	**2,052,396**	**1,387,946**	**48%**

Appendix III - Condensed Consolidated Cash Flow Statement

USD'000	1H 2021	1H 2020	Var.
Cash (used in)/generated from operations	(44,105)	19,581	-325%
Income tax paid	(69,425)	(14,308)	385%
Income tax refund received	7,168	3,176	126%
Net cash (used in)/generated from operating activities	**(106,362)**	**8,449**	**-1359%**
Net cash used in investing activities	**(214,485)**	**(37,861)**	**467%**
Net cash generated from financing activities	**1,015,998**	**220,942**	**360%**
Net increase in cash and cash equivalents	**695,151**	**191,530**	**263%**
Cash and cash equivalents at 1 January	**1,002,077**	**280,077**	**258%**
Effect of foreign exchange rate changes	2,182	(334)	-753%
Cash and cash equivalents at 30 June	**1,699,410**	**471,273**	**261%**